Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
CBN, the cannabis compound flooding the sleep supplement market, may be more habit-forming than its mild reputation suggests. New research from the University of Connecticut found that mice repeatedly exposed to CBN developed tolerance and withdrawal symptoms — effects similar to those seen with THC. Scientists say the long-term risks in humans are still largely unknown, and urge consumers to proceed with caution.
Cannabinol (CBN) has become a darling of the wellness world, marketed as a safe, natural sleep aid in gummies, tinctures, and capsules. But new research from the University of Connecticut is raising some important questions. Scientists found that mice given CBN twice daily for three days developed tolerance to the compound — and when it was taken away, they showed physical withdrawal symptoms like head twitching and paw fluttering, hallmarks of drug dependence.
Perhaps most notable: mice trained to recognize THC's psychoactive effects responded similarly to CBN, suggesting the two compounds share overlapping effects on the brain's receptor systems. CBN also showed anti-inflammatory properties at lower doses, hinting at potential therapeutic value — but it also appeared to suppress immune defenses during a simulated bacterial challenge, raising additional safety considerations.
Key Takeaways:
Why it matters: CBN products are widely available and largely unregulated, yet the science hasn't kept pace with the marketing. Researchers caution that, like several "safe" sleep aids before it, CBN's risks may be underestimated — and consumers and clinicians alike should approach it with eyes wide open.
